Short Interest in TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Expands By 22.8%

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) saw a large growth in short interest in December. As of December 15th, there was short interest totalling 57,600 shares, a growth of 22.8% from the November 30th total of 46,900 shares. Based on an average trading volume of 35,900 shares, the days-to-cover ratio is presently 1.6 days. Currently, 1.7% of the shares of the company are short sold.

Insider Buying and Selling

In other TriSalus Life Sciences news, major shareholder Equity Ab Frankenius bought 62,972 shares of the business’s stock in a transaction that occurred on Tuesday, December 17th. The stock was purchased at an average price of $3.97 per share, for a total transaction of $249,998.84. Following the completion of the transaction, the insider now owns 6,230,748 shares of the company’s stock, valued at $24,736,069.56. This trade represents a 1.02 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last ninety days, insiders bought 70,012 shares of company stock valued at $281,235. 32.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Highbridge Capital Management LLC purchased a new position in shares of TriSalus Life Sciences in the 2nd quarter worth approximately $1,184,000. Wolverine Asset Management LLC bought a new stake in shares of TriSalus Life Sciences in the 2nd quarter worth about $240,000. Duquesne Family Office LLC grew its holdings in TriSalus Life Sciences by 35.1% during the 2nd quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock valued at $2,357,000 after purchasing an additional 110,966 shares during the last quarter. MSD Partners L.P. bought a new stake in TriSalus Life Sciences in the third quarter worth about $184,000. Finally, Walleye Capital LLC purchased a new position in shares of TriSalus Life Sciences during the third quarter valued at approximately $66,000. Hedge funds and other institutional investors own 2.58% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on TLSI shares. Northland Securities started coverage on shares of TriSalus Life Sciences in a report on Friday, October 25th. They set an “outperform” rating and a $12.50 price objective for the company. Cantor Fitzgerald assumed coverage on shares of TriSalus Life Sciences in a research report on Tuesday, December 17th. They set an “overweight” rating and a $10.00 target price for the company. Northland Capmk upgraded shares of TriSalus Life Sciences to a “strong-buy” rating in a report on Friday, October 25th. Roth Capital raised shares of TriSalus Life Sciences to a “strong-buy” rating in a report on Monday, November 11th. Finally, Canaccord Genuity Group cut their price objective on TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating for the company in a research report on Friday, November 15th. Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $11.79.

TriSalus Life Sciences Stock Up 2.5 %

TLSI stock opened at $4.96 on Tuesday. The company has a fifty day simple moving average of $4.19 and a two-hundred day simple moving average of $4.84. TriSalus Life Sciences has a 52 week low of $3.50 and a 52 week high of $10.42. The firm has a market capitalization of $151.25 million, a P/E ratio of -1.99 and a beta of 0.56.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.